Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines
Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2023-11, Vol.78 (5), p.1625-1653 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1653 |
---|---|
container_issue | 5 |
container_start_page | 1625 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 78 |
creator | Gong, Lijun Wei, Fang Gonzalez, Frank J Li, Guolin |
description | Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made in understanding the pathogenesis and clinical consequences of hepatic fibrosis, therapeutic strategies for this disease are limited. Preclinical studies suggest that peroxisome proliferator-activated receptor alpha plays an important role in preventing the development of liver fibrosis by activating genes involved in detoxifying lipotoxicity and toxins, transrepressing genes involved in inflammation, and inhibiting activation of hepatic stellate cells. Given the robust preclinical data, several peroxisome proliferator-activated receptor alpha agonists have been tested in clinical trials for liver fibrosis. Here, we provide an update on recent progress in understanding the mechanisms by which peroxisome proliferator-activated receptor alpha prevents fibrosis and discuss the potential of targeting PPARα for the development of antifibrotic treatments. |
doi_str_mv | 10.1097/HEP.0000000000000182 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10681123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2773114903</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-c1f791084e93e87405da586db83eac3bddcaad54fbd255cde4b9c602ef0a6ef93</originalsourceid><addsrcrecordid>eNpdUctOHTEMjVAruND-QYWy7GYgr3mEDaoQcJGQ2gVdR57EuTfVzGRIclH79wziIYo3lu3jcywfQr5xdsKZbk_Xl79O2PvgndgjK16LtpKyZp_IiomWVZpLfUAOc_6zYLQS3T45kE0jmkaJFdmucYYSLPWhTzGHfEbvIG2whGlDZ0zxb8hxRDqnOASPCUpMFdgSHqCgowktzkuLwjBvgfoURzqi3cIU8khLXAoXbJgwfyGfPQwZv77kI_L76vLuYl3d_ry-ufhxW1nFdKks963mrFOoJXatYrWDumtc30kEK3vnLICrle-dqGvrUPXaNkygZ9Cg1_KInD_zzrt-Ebc4lQSDmVMYIf0zEYL5fzKFrdnEB8NZ03Eu5MLw_YUhxfsd5mLGkC0OA0wYd9mItpWcK82eoOoZapff5YT-TYcz8-SSWVwyH11a1o7f3_i29GqLfASdCpG3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2773114903</pqid></control><display><type>article</type><title>Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gong, Lijun ; Wei, Fang ; Gonzalez, Frank J ; Li, Guolin</creator><creatorcontrib>Gong, Lijun ; Wei, Fang ; Gonzalez, Frank J ; Li, Guolin</creatorcontrib><description>Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made in understanding the pathogenesis and clinical consequences of hepatic fibrosis, therapeutic strategies for this disease are limited. Preclinical studies suggest that peroxisome proliferator-activated receptor alpha plays an important role in preventing the development of liver fibrosis by activating genes involved in detoxifying lipotoxicity and toxins, transrepressing genes involved in inflammation, and inhibiting activation of hepatic stellate cells. Given the robust preclinical data, several peroxisome proliferator-activated receptor alpha agonists have been tested in clinical trials for liver fibrosis. Here, we provide an update on recent progress in understanding the mechanisms by which peroxisome proliferator-activated receptor alpha prevents fibrosis and discuss the potential of targeting PPARα for the development of antifibrotic treatments.</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1097/HEP.0000000000000182</identifier><identifier>PMID: 36626642</identifier><language>eng</language><publisher>United States</publisher><subject>Carcinoma, Hepatocellular - pathology ; Fibrosis - etiology ; Fibrosis - genetics ; Fibrosis - metabolism ; Humans ; Inflammation - metabolism ; Liver - pathology ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - etiology ; Liver Cirrhosis - metabolism ; Liver Neoplasms - pathology ; Non-alcoholic Fatty Liver Disease - pathology ; PPAR alpha - genetics ; PPAR alpha - metabolism</subject><ispartof>Hepatology (Baltimore, Md.), 2023-11, Vol.78 (5), p.1625-1653</ispartof><rights>Copyright © 2023 American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-c1f791084e93e87405da586db83eac3bddcaad54fbd255cde4b9c602ef0a6ef93</citedby><cites>FETCH-LOGICAL-c409t-c1f791084e93e87405da586db83eac3bddcaad54fbd255cde4b9c602ef0a6ef93</cites><orcidid>0000-0002-8862-3928 ; 0000-0001-5535-0073 ; 0000-0001-8247-1217 ; 0000-0002-7990-2140</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36626642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gong, Lijun</creatorcontrib><creatorcontrib>Wei, Fang</creatorcontrib><creatorcontrib>Gonzalez, Frank J</creatorcontrib><creatorcontrib>Li, Guolin</creatorcontrib><title>Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made in understanding the pathogenesis and clinical consequences of hepatic fibrosis, therapeutic strategies for this disease are limited. Preclinical studies suggest that peroxisome proliferator-activated receptor alpha plays an important role in preventing the development of liver fibrosis by activating genes involved in detoxifying lipotoxicity and toxins, transrepressing genes involved in inflammation, and inhibiting activation of hepatic stellate cells. Given the robust preclinical data, several peroxisome proliferator-activated receptor alpha agonists have been tested in clinical trials for liver fibrosis. Here, we provide an update on recent progress in understanding the mechanisms by which peroxisome proliferator-activated receptor alpha prevents fibrosis and discuss the potential of targeting PPARα for the development of antifibrotic treatments.</description><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Fibrosis - etiology</subject><subject>Fibrosis - genetics</subject><subject>Fibrosis - metabolism</subject><subject>Humans</subject><subject>Inflammation - metabolism</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - metabolism</subject><subject>Liver Neoplasms - pathology</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>PPAR alpha - genetics</subject><subject>PPAR alpha - metabolism</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUctOHTEMjVAruND-QYWy7GYgr3mEDaoQcJGQ2gVdR57EuTfVzGRIclH79wziIYo3lu3jcywfQr5xdsKZbk_Xl79O2PvgndgjK16LtpKyZp_IiomWVZpLfUAOc_6zYLQS3T45kE0jmkaJFdmucYYSLPWhTzGHfEbvIG2whGlDZ0zxb8hxRDqnOASPCUpMFdgSHqCgowktzkuLwjBvgfoURzqi3cIU8khLXAoXbJgwfyGfPQwZv77kI_L76vLuYl3d_ry-ufhxW1nFdKks963mrFOoJXatYrWDumtc30kEK3vnLICrle-dqGvrUPXaNkygZ9Cg1_KInD_zzrt-Ebc4lQSDmVMYIf0zEYL5fzKFrdnEB8NZ03Eu5MLw_YUhxfsd5mLGkC0OA0wYd9mItpWcK82eoOoZapff5YT-TYcz8-SSWVwyH11a1o7f3_i29GqLfASdCpG3</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Gong, Lijun</creator><creator>Wei, Fang</creator><creator>Gonzalez, Frank J</creator><creator>Li, Guolin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8862-3928</orcidid><orcidid>https://orcid.org/0000-0001-5535-0073</orcidid><orcidid>https://orcid.org/0000-0001-8247-1217</orcidid><orcidid>https://orcid.org/0000-0002-7990-2140</orcidid></search><sort><creationdate>20231101</creationdate><title>Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines</title><author>Gong, Lijun ; Wei, Fang ; Gonzalez, Frank J ; Li, Guolin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-c1f791084e93e87405da586db83eac3bddcaad54fbd255cde4b9c602ef0a6ef93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Fibrosis - etiology</topic><topic>Fibrosis - genetics</topic><topic>Fibrosis - metabolism</topic><topic>Humans</topic><topic>Inflammation - metabolism</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - metabolism</topic><topic>Liver Neoplasms - pathology</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>PPAR alpha - genetics</topic><topic>PPAR alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gong, Lijun</creatorcontrib><creatorcontrib>Wei, Fang</creatorcontrib><creatorcontrib>Gonzalez, Frank J</creatorcontrib><creatorcontrib>Li, Guolin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gong, Lijun</au><au>Wei, Fang</au><au>Gonzalez, Frank J</au><au>Li, Guolin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>78</volume><issue>5</issue><spage>1625</spage><epage>1653</epage><pages>1625-1653</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><abstract>Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made in understanding the pathogenesis and clinical consequences of hepatic fibrosis, therapeutic strategies for this disease are limited. Preclinical studies suggest that peroxisome proliferator-activated receptor alpha plays an important role in preventing the development of liver fibrosis by activating genes involved in detoxifying lipotoxicity and toxins, transrepressing genes involved in inflammation, and inhibiting activation of hepatic stellate cells. Given the robust preclinical data, several peroxisome proliferator-activated receptor alpha agonists have been tested in clinical trials for liver fibrosis. Here, we provide an update on recent progress in understanding the mechanisms by which peroxisome proliferator-activated receptor alpha prevents fibrosis and discuss the potential of targeting PPARα for the development of antifibrotic treatments.</abstract><cop>United States</cop><pmid>36626642</pmid><doi>10.1097/HEP.0000000000000182</doi><tpages>29</tpages><orcidid>https://orcid.org/0000-0002-8862-3928</orcidid><orcidid>https://orcid.org/0000-0001-5535-0073</orcidid><orcidid>https://orcid.org/0000-0001-8247-1217</orcidid><orcidid>https://orcid.org/0000-0002-7990-2140</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2023-11, Vol.78 (5), p.1625-1653 |
issn | 0270-9139 1527-3350 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10681123 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Carcinoma, Hepatocellular - pathology Fibrosis - etiology Fibrosis - genetics Fibrosis - metabolism Humans Inflammation - metabolism Liver - pathology Liver Cirrhosis - drug therapy Liver Cirrhosis - etiology Liver Cirrhosis - metabolism Liver Neoplasms - pathology Non-alcoholic Fatty Liver Disease - pathology PPAR alpha - genetics PPAR alpha - metabolism |
title | Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T08%3A22%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatic%20fibrosis:%20Targeting%20peroxisome%20proliferator-activated%20receptor%20alpha%20from%20mechanism%20to%20medicines&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Gong,%20Lijun&rft.date=2023-11-01&rft.volume=78&rft.issue=5&rft.spage=1625&rft.epage=1653&rft.pages=1625-1653&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1097/HEP.0000000000000182&rft_dat=%3Cproquest_pubme%3E2773114903%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2773114903&rft_id=info:pmid/36626642&rfr_iscdi=true |